chartexchange

Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress

GlobeNewswire Inc. | Nov 10, 2026 4:16 PM EST

CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR,  56% confirmed DCR, and median PFS of 5.6 months

Read original article